Comparative Pharmacology
Head-to-head clinical analysis: ANSAID versus IBUPROFEN LYSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSAID versus IBUPROFEN LYSINE.
ANSAID vs IBUPROFEN LYSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
Ibuprofen lysine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
200-300 mg orally or rectally twice daily, or 100 mg orally three times daily; maximum 300 mg/day.
200-800 mg orally every 6-8 hours as needed; maximum 2400 mg/day. Intravenous: 400-800 mg every 6 hours; maximum 3.2 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours. No accumulation occurs with normal dosing; however, in elderly or hepatic impairment, half-life may be prolonged.
2–4 hours in adults; extended to 4–6 hours in neonates. In severe hepatic or renal impairment, half-life may increase up to 8–10 hours.
Renal excretion of metabolites (approximately 95%), with less than 5% excreted unchanged. Fecal elimination accounts for minor amounts.
Renal excretion of metabolites and conjugates accounts for >90% of elimination; less than 1% is excreted unchanged in urine. Fecal excretion is minimal (<5%).
Category C
Category D/X
NSAID
NSAID